REGENXBIO Inc. (RGNX)
NASDAQ: RGNX
· Real-Time Price · USD
8.96
-0.10 (-1.10%)
At close: Aug 15, 2025, 10:04 AM
-1.10% (1D)
| Bid | 8.8 |
| Market Cap | 452.41M |
| Revenue (ttm) | 155.78M |
| Net Income (ttm) | -175.57M |
| EPS (ttm) | -3.44 |
| PE Ratio (ttm) | -2.6 |
| Forward PE | -5.15 |
| Analyst | Buy |
| Ask | 9.07 |
| Volume | 84,129 |
| Avg. Volume (20D) | 875,588 |
| Open | 9.10 |
| Previous Close | 9.06 |
| Day's Range | 8.93 - 9.17 |
| 52-Week Range | 5.04 - 13.48 |
| Beta | 1.11 |
About RGNX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RGNX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RGNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
REGENXBIO has released their quartely earnings
on Aug 7, 2025:
Next Earnings Release
REGENXBIO Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-17.06%
Regenxbio shares are trading lower after the compa...
Unlock content with
Pro Subscription
3 months ago
+2.63%
RGNX stock has given up its prior gain. Regenxbio shares were trading higher following Q1 financial results and after the company announced FDA acceptance and priority review of BLA for RGX-121.
2 months ago · seekingalpha.com
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter SyndromeREGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA d...
